Track topics on Twitter Track topics that are important to you
The fixed dose combination FDC of netupitant and palonosetron is a product proposed for the treatment of the most common side effects of chemotherapynausea and vomiting. The product is currently in its third stage of trial. Netupitant is a novel and a NK1 receptor antagonist, and palonosetron is a secondgeneration 5HT3 receptor antagonist. While netupitant was not available in the drug market earlier, palonosetron drugs were already present under trade names Paloxi, Onicit, and Aloxi. The combination drug is expected to overcome major problems associated with the current mode of treatment of the CINV condition, which involves the use of 5HT3 receptor antagonists.nnThe netupitantpalonosetron FDC market is driven by rise in number of patients who undergo chemotherapy. The market is segmented on the basis of patient pool and geography. Currently, pharmaceutical companies are increasingly investing in the further discovery of FDC drugs to achieve increased industry leading breadth and depth of clinical research.nnHowever, factors such as adverse effect of netupitantpalonosetron FDC and high cost of drugs for patients act as restraints for the growth and development of the market. The new approaches and advancement in netupitantpalonosetron FDC market is the development in efficacy and potential of new FDC drugs. The foundation of combination therapy is projected to build up in broad spectrum. Netupitantndash;palonosetron, by trade name of Akynzeo, is approved and witnesses an increasing traction in the U.S. and European region.nnThe classes of drugs used in the treatment of CINV are 5HT3 receptor antagonists, NK1 receptor antagonists, corticosteroids, dopamine antagonists, benzodiazepines, and cannabinoids. However, Akynzeo is mostly used in the treatment, and is helpful in the prevention of nausea and vomiting due to longlasting action, with no major adverse effects.nnGeographically, the global netupitantpalonosetron FDC market is segmented into North America, Europe, AsiaPacific, and LAMEA. In terms of growth rate, AsiaPacific is expected to remain dominant over the forecast period, followed by Europe. North America, on the other hand, is expected to increase at a steady pace due to its steady growth in number of cancer patients opting for chemotherapy.nnMajor players profiled in the report includes Helsinn Holding S.A., Heron Therapeutics, Inc., Eisai Pharmaceutical Pvt. Ltd., and Tesaro, Inc.nnKEY BENEFITS FOR STAKEHOLDERS:nnnnThis report provides an extensive analysis of the current amp; emerging market trends and dynamics in the global netupitantndash;palonosetron FDC market.nnThis report entails the detailed quantitative analysis of the current trends and future estimations from 2014 to 2022, which assists to identify the prevailing market opportunities.nnThis study evaluates competitive landscape and value chain to understand the competitive environment across the geographies.nnComprehensive analysis of factors that drive and restrict the growth of the market is provided.nnnKEY MARKET SEGMENTS:nnnnBy Patient PoolnnBy GeographynnnnnNorth AmericannnEuropennnAsiaPacificnnnLAMEAnnnnnNEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...